UCB (OTCMKTS:UCBJY) Sees Strong Trading Volume – What’s Next?

UCB SA (OTCMKTS:UCBJY) shares saw strong trading volume on Monday . 34,053 shares were traded during mid-day trading, an increase of 16% from the previous session’s volume of 29,363 shares.The stock last traded at $148.11 and had previously closed at $149.07.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Wolfe Research upgraded UCB to a “strong-buy” rating in a research note on Monday, February 23rd. Zacks Research lowered UCB from a “strong-buy” rating to a “hold” rating in a report on Monday, November 3rd. Two equities research analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, UCB currently has an average rating of “Buy”.

UCB Trading Down 2.0%

The company has a debt-to-equity ratio of 0.29, a current ratio of 1.35 and a quick ratio of 1.01. The stock’s 50-day simple moving average is $151.56 and its 200 day simple moving average is $138.74.

About UCB

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.